FDA Approves THIAMINE HYDROCHLORIDE — Lifestar Pharma LLC
On July 31, 2026, Lifestar Pharma LLC received FDA approval to manufacture and market the intramuscular formulation of generic thiamine hydrochloride, potentially providing a cost-effective alternative to existing injectable supplies. This approval positions the company to capitalize on existing patent cliffs while bolstering the generic supply chain for a critical essential medication used to treat B vitamin deficiencies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed